Articles tagged with Antibodies
A new study shows an antibody that prevents dengue disease also protects mice from Zika. Administering the antibody soon after infection can protect fetuses from Zika-related birth defects.
A new study by University of Nottingham researchers found that a positive mood on the day of flu vaccination can significantly increase its protective effect. The study, which measured factors such as mood, physical activity and diet, showed that good mood was associated with higher levels of antibody after vaccination.
Researchers found that a combination of two broadly-neutralizing HIV-1 antibodies protected primates against infection with a mixed population of HIV viruses. The findings suggest that combination therapies might be essential to prevent HIV in people, highlighting the need for regimens that protect against several targets.
A new study reveals how the immune system avoids becoming cancerous by using a hair-trigger protein called Tia1. This protein controls the production of proteins needed to fix damaged DNA, allowing B cells to produce effective antibodies while preventing lasting harm.
Researchers have found a way to generate long-lasting immune cells that can respond to and stop HIV virus infection. The team demonstrated that a modified gp140 protein approach improves B-cell responses, boosting the ability of B-cells to make protective antibodies against HIV.
Researchers have created antibody-recruiting molecules targeting fungi (ARM-Fs) that can attach to fungal cell walls and recruit human antibodies to combat infections. These small molecules offer a new strategy for treating fungal diseases affecting thousands of people each year.
Researchers at Scripps Research Institute discover a way to reprogram mature skin-like cells into stem cells using antibodies, potentially reducing mutations and improving properties. This method could lead to personalized cell therapies and organ regeneration.
Rice University scientists have developed a method to efficiently modify natural antibodies that can deliver drugs to target cells by adding rhodium, a rare transition metal. The new technique allows labs to test the relative function of various antibody sources and antigen targets to see which will work best on tumor cells.
Researchers at Hokkaido University have developed a chimeric anti-PD-L1 antibody that induces immune responses and tumor regression in dogs with malignant cancers. The antibody targets PD-L1-positive cancers, including oral malignant melanoma and undifferentiated sarcoma.
Research published in Annals of the Rheumatic Diseases found a link between prolonged use of oral contraceptives and reduced risk of developing rheumatoid arthritis. However, breastfeeding was not associated with a significant protective effect after accounting for influential factors.
A new study by Texas Tech University Health Sciences Center El Paso researchers explores the impact of prior West Nile virus exposure on Zika infection. The team collected blood samples from 500 individuals and tested for West Nile antibodies to determine whether previous exposure could inhibit or enhance Zika infection severity.
Scientists have discovered a specific type of immune regulatory cell, T follicular regulatory cells (Tfr), in patients with Sjögren syndrome, an autoimmune disease. Blood Tfr cells are immature and unable to suppress antibody production, but their levels increase in response to flu vaccine exposure.
Researchers at Arizona State University have developed a plant-based Zika vaccine that is more potent, safer and cheaper to produce than existing alternatives. The vaccine targets the DIII domain of the Zika virus and has been shown to induce 100% protection against multiple Zika virus strains in mice.
A new portable platform enables sensitive and rapid diagnostic testing in resource-limited settings, detecting telltale markers of disease as accurately as the most sensitive tests on the market. The D4 assay can identify a disease biomarker in as few as 15 minutes.
A new study found that prior dengue or yellow fever exposure does not increase susceptibility to severe Zika virus infection in rhesus macaques. The researchers observed no significant differences in clinical factors between previously infected and uninfected monkeys after Zika virus infection.
Researchers found that treating patients with IdeS drug before transplantation significantly reduced donor-specific antibodies, allowing successful kidney transplants. The enzyme, produced by Streptococcus pyogenes, can remove organ-rejecting antibodies, making kidney transplantation possible.
Researchers found that prior vaccination in pregnant women did not significantly affect the transfer of flu antibodies to their babies, contradicting initial concerns. Weakened maternal immune responses from repeated flu shots also hindered peak antibody levels.
Researchers have developed a new method to generate specific human antibodies in the laboratory using nanoparticles. This technique can produce high-affinity antibodies within days, offering potential for rapid therapeutic antibody production and accelerated vaccine development.
A team of researchers has successfully manufactured microscopic versions of silkworm cocoons, which can store and protect sensitive molecular materials. The tiny capsules, made from silk nano-fibrils, have the potential to increase the stability and lifetime of antibodies used in pharmaceuticals for treating severe diseases.
A team led by Prof. Arne Skerra has identified an antibody that tightly binds benzopyrene, a widespread environmental toxin linked to cancer. This breakthrough could lead to the development of antibodies to separate aromatic hydrocarbons from contaminated drinking water.
Tulane University has received a $12 million grant to test a promising drug treatment for Lassa fever and develop a vaccine against the deadly disease. The vaccine targets a recently discovered key antibody target on the surface of the virus, which can block it from infecting host cells.
Researchers at TUM have identified an antibody that tightly binds benzo[a]pyrene, a widespread environmental toxin linked to cancer. This breakthrough discovery may lead to the development of antibodies against other PAHs and improved methods to separate contaminants from drinking water.
A recent study by Duke University researchers demonstrates a vaccine approach that appears to protect fetuses from congenital CMV infection. The findings, published in JCI Insight, suggest potent antibodies can prevent viral transmission and severe disease in developing fetuses.
A recent study by the University of Zurich found that exposure to sialic acid from farm animals can prevent asthma in children. This protective effect is due to an anti-inflammatory response triggered by regulatory T-cells, which dampen incorrect immune responses.
Researchers found that maternal antibodies against HSV-1 can travel to the nervous systems of unborn babies, preventing the development and spread of infection during birth. This protection may help prevent serious brain disease related to these conditions in fetuses and newborns.
Researchers at CNIC reveal CTCF's crucial role in antibody generation and germinal center formation, shedding light on the immune response mechanisms. The study highlights the importance of CTCF for maintaining proper immune function and has implications for vaccine research.
Researchers at Cornell University discovered a new way to measure tiny amounts of antibodies in foals, helping to understand how quickly they start producing their own. This will aid in optimizing vaccination schedules for young horses.
Researchers have demonstrated a new therapeutic approach that can re-build and strengthen bone, offering hope for individuals with the debilitating bone cancer, multiple myeloma. The treatment targets a protein called sclerostin, which halts bone formation, and found to double bone volume in some mice.
Researchers at Duke University Medical Center have discovered a new antibody that can restore the effectiveness of chemotherapy rituximab in leukemia patients with natural resistance. The study found that adding the antibody to rituximab increased cancer cell death by 45% in five out of 11 patients.
Researchers develop Affimer technology to replicate antibodies, providing a more robust, smaller, and easier-to-modify alternative. This tool enables scientists to study molecular behavior and reactions with ease, leading to breakthroughs in disease research.
Researchers at Université de Genève have developed a new test to detect anti-phospholipid antibody syndrome (APS), an autoimmune disease affecting around 0.5% of the population. The test targets the specific antibody that binds to cells, producing pro-inflammatory and pro-thrombotic factors, offering improved accuracy and standardization.
Researchers elucidate mechanisms behind synaptic vesicle motion, finding that type, size of synapse and vesicle composition impact motility. Tracking vesicles reveals active transport to specific destinations, providing clues for neuronal diseases.
Researchers found that Zika viral load and dengue antibodies were not associated with severe symptoms or fetal harm, contradicting previous theories. The study's findings suggest a lack of correlation between the amount of virus in the blood and severity of symptoms in pregnant women.
Researchers developed a 3-D crystal structure of the disease's molecular interactions with a neural receptor, providing a clear view of how it attacks and destroys proteins. The model could accelerate research and lead to new therapies for myasthenia gravis, which affects an estimated 36,000 to 60,000 Americans annually.
Scientists at Johns Hopkins created a nanoparticle that carries two different antibodies to simultaneously switch off cancer cells' defensive properties while switching on a robust anticancer immune response in mice. The 'immunoswitch' particles dramatically slowed the growth of mouse melanoma and colon cancer, even eradicating tumors.
Researchers developed an anti-PD-1 antibody that blocks PD-1/PD-L1 interaction, reinvigorating antivirus immune response and decreasing BLV counts. The new treatment could be effective against various intractable infectious diseases in cows.
Researchers from Florida Atlantic University identified 11 cross-reactive terrestrial-specific antibodies for dolphins, allowing them to assess changes in immune cell populations. The study shows significant differences in the absolute number of cells expressing specific markers within lymphocyte and monocyte fractions.
Researchers have discovered a molecular mechanism behind prion protein's role in neurodegenerative diseases, including Creutzfeldt-Jakob and Alzheimer's. The study found that copper biases the prion protein towards its 'off' state, which reduces toxic signals to nerve cells.
Researchers use a redesigned spider venom peptide to deliver biomacromolecules like antibodies into cells, enabling tracking and interaction with target proteins. The technology improves understanding of protein behavior and could lead to new treatments and drug delivery.
AbeXXa Biologics identifies targets for cancer treatment from thousands of intracellular proteins, potentially resulting in effective immunotherapies for broad patient groups. The company is developing T cell receptor-like antibody-drug complexes to kill tumor cells with low peptide/HLA targets.
Researchers at Brigham and Women's Hospital have developed an antibody that can precisely target regulatory T cells, unleashing the immune system to kill cancer cells. The antibody decreased tumor growth in models of melanoma, glioblastoma, and colorectal carcinoma.
Researchers at Stanford University School of Medicine have shown that antibodies to PD-1 and PD-L1 can also prompt immune cells called macrophages to engulf and devour cancer cells, expanding the use of this cancer treatment.
An international team of researchers has identified two receptors on blood vessel cells in the brain that can be blocked to prevent pneumococci from entering. Blocking these receptors with antibodies may lead to a new therapeutic strategy for pneumococcal meningitis.
Scientists at EPFL developed an antibody-linked biosensor that can track drug concentration in the blood by changing color, enabling patients to monitor their treatment levels at home. The biosensor can be adapted to detect virtually unlimited number of molecules.
A team of chemists from Italy and Canada has developed a molecular slingshot made of DNA that can deliver drugs to precise locations in the human body. The device uses a synthetic DNA strand with anchoring moieties that bind to target antibodies, releasing a loaded drug upon recognition.
A research team at Rockefeller University has identified a potent new weapon against the Zika virus: Z004, an antibody that neutralizes the virus and could be used to create a vaccine. The discovery was made by analyzing blood samples from people who had been infected with the virus.
A new study found that desensitizing patient antibodies can reduce the risk of heart transplant rejection in high immunological risk patients. Patients with high levels of anti-HLA antibodies had similar survival rates to those without DSA, but experienced more bleeding complications due to plasmapheresis.
Scientists have discovered clues into how a destructive autoimmune disease works using a unique microscope capable of illuminating living cell structures. They were able to see clusters of antibodies atop astrocytes, the brain cell target of the autoimmune response in neuromyelitis optica.
A team of scientists has discovered an antibody that can measure tau levels in the blood, which accurately reflects brain damage. This breakthrough could lead to a non-invasive test for tau-based diseases, monitoring disease progression, and measuring treatment effectiveness.
MIT researchers have developed a way to make extremely high-resolution images of tissue samples, allowing scientists to see complex patterns in brain synapses and potentially map neural circuits. The new technique uses a tissue-expansion technique to boost resolution to about 25 nanometers.
Engineers at MIT have developed a microfluidic technique to capture and count circulating plasma cells from small samples of blood, potentially providing a less painful test for multiple myeloma. The device uses conventional blood draws and can detect the ratio of different antibodies produced by cancerous and healthy cells.
Researchers have developed a biomarker that can detect early signs of HPV16 E6 antibody presence in blood samples, indicating high risk of developing oropharyngeal cancer. The test is highly specific but not suitable for larger population groups due to low new case incidence rates.
Researchers have developed an effective antibody against radiation-induced pulmonary fibrosis, a debilitating side effect of lung cancer treatment. The antibody targets connective tissue growth factor (CTGF), reversing fibrotic transformation and improving pulmonary function in mice.
Researchers developed a new treatment pathway removing antibodies from the bloodstream to reduce chronic infections and hospital stays. The approach showed positive outcomes for two patients with resistant Pseudomonas aeruginosa lung infections.
A new fluorescent probe developed by Michigan Technological University researchers has the potential to improve cancer surgery outcomes. The probe uses a near-infrared fluorescence that can penetrate deep tissues, reducing background noise and increasing precision for surgeons.
Researchers at Boston Children's Hospital report achieving strong vaccine responses in newborn animals and monkeys using a new adjuvant formulation. The study demonstrates the potential for a single-dose vaccine to protect against life-threatening infections, promising to reduce infant mortality globally.
Researchers at Uppsala University have discovered that antibodies against cartilage protein collagen II are associated with a good prognosis in rheumatoid arthritis. The study found that patients with these antibodies showed increased signs of inflammation during the first six months after diagnosis, but no difference later on.
Researchers developed a new drug delivery method using antibody-drug conjugates (ADCs) that show high precision and stability. The method successfully treated hard-to-treat solid and liquid tumors, including HER2 breast cancer and CD138 multiple myeloma, without harming healthy cells.
A lab study identifies mutations in hepatitis C virus that evade the natural immune system and vaccines, highlighting a major barrier to vaccine development. Researchers found that these mutations occur outside of traditional vaccine targets and confer resistance to commonly used antibodies.
A new study found that an antibody targeting CD47 can effectively treat five types of pediatric brain cancer in mice, with no harm to healthy brain cells. The treatment, developed at Stanford, has shown promising results in preclinical trials and is expected to reach clinical trials in children with brain cancer in one to two years.